United States · biotech/health
United States · biotech/healthSpringWorks Therapeutics
SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.
Public · NASDAQ:SWTXFor profit
Against its peers
Set against 435 biotech/health companies in United States. The ring marks the typical peer.
Across all 5.9M companies: larger than 92% of those with a size listed; older than 5% of those with a founding year; website ranked #3,866,341 in the world, about 3k visits a month.
About SpringWorks Therapeutics
BiopharmaBiotechnologyTherapeutics
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves.
$1.0B
raised in total, currency not stated across 5 rounds
Last raised Dec 2023, 2 years ago
- Rounds
- 5
- Latest round
- Post ipo equity
- Investors
- 181 leading
Key facts
Who started it and how it trades.
- Founded by
- Lara S. Sullivan, Yoni Falkson
Every detail we hold
Everything the source datasets list about SpringWorks Therapeutics, field by field. Contact details are held but never shown.
The company7 fields
- Name
- SpringWorks Therapeutics
- Type
- For profit
- Status
- Public · NASDAQ:SWTX
- Founded
- 2017
- Founders
- Lara S. Sullivan, Yoni Falkson
- Industry
- biotech/health
- Categories
- Biopharma, Biotechnology, Therapeutics
Where3 fields
- City
- Stamford
- Country
- United States
- Markets
- East Coast, New England, Northeastern US
Size and reach3 fields
- Staff band
- 251-500
- Web traffic rank
- #3,866,341
- Monthly web visits
- 2,989
Show 10 more fieldsShow fewer fields
Funding, as listed8 fields
- Total
- 1,015,500,000 (currency not stated)
- Rounds
- 5
- Latest round
- Post ipo equity
- Latest round date
- Dec 2023
- Investors
- 18
- Lead investors
- 1
- Stock listing
- NASDAQ:SWTX
- Listing status
- public
About this record2 fields
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
SpringWorks Therapeutics reported its first quarter 2024 financial results, highlighting recent business updates. The company also completed the submission of a new drug application to the FDA for Mirdametinib for the treatment of children and adults with NF1-PN. Additionally, SpringWorks Therapeutics announced data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company showed market leadership with a jump to an 83 RS rating and reported Q4 and full year 2023 financial results.
Companies like SpringWorks Therapeutics
biotech/health in United States.
Revolution MedicinesRedwood City · 251-500 peoplefounded 2 years earlier
FreenomeSouth San Francisco · 501-1000 peoplefounded 3 years earlier
Relay TherapeuticsCambridge · 251-500 peoplefounded 1 years earlier
Denali TherapeuticsSan Francisco · 251-500 peoplefounded 4 years earlier
Arcus BiosciencesHayward · 101-250 peoplefounded 2 years earlierBuild a lead list
435 biotech/health companies in United States, filtered by size, age and reach, ready to export with emails on Pro.